Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

459
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
459
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.1K
Development of Immunocompetence01:22

Development of Immunocompetence

494
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
494
Cancer Vaccines01:30

Cancer Vaccines

548
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
548
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avian Immunoglobulin Y Antibodies Targeting the Protruding or Shell Domain of Norovirus Capsid Protein Neutralize Norovirus Replication in the Human Intestinal Enteroid System.

Vaccines·2025
Same author

A Nanoparticle Comprising the Receptor-Binding Domains of Norovirus and <i>Plasmodium</i> as a Combination Vaccine Candidate.

Vaccines·2025
Same author

A Pseudovirus Nanoparticle Displaying the Vaccinia Virus L1 Protein Elicited High Neutralizing Antibody Titers and Provided Complete Protection to Mice against Mortality Caused by a Vaccinia Virus Challenge.

Vaccines·2024
Same author

A Viral Protein 4-Based Trivalent Nanoparticle Vaccine Elicited High and Broad Immune Responses and Protective Immunity against the Predominant Rotaviruses.

ACS nano·2024
Same author

Pseudovirus Nanoparticles Displaying <i>Plasmodium</i> Circumsporozoite Proteins Elicited High Titers of Sporozoite-Binding Antibody.

Vaccines·2023
Same author

The αTSR Domain of <i>Plasmodium</i> Circumsporozoite Protein Bound Heparan Sulfates and Elicited High Titers of Sporozoite Binding Antibody After Displayed by Nanoparticles.

International journal of nanomedicine·2023

Related Experiment Video

Updated: Oct 8, 2025

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR
15:16

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR

Published on: July 22, 2012

17.4K

Norovirus Vaccines: Current Clinical Development and Challenges.

Ming Tan1,2

  • 1Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.

Pathogens (Basel, Switzerland)
|December 28, 2021
PubMed
Summary

Developing effective norovirus vaccines is challenging due to viral diversity and research hurdles. However, virus-like particle (VLP) vaccines show promise for broad protection against norovirus infections.

Keywords:
antiviralgastroenteritisimmunogenicitynorovirusvaccine

More Related Videos

Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity
12:57

Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity

Published on: November 16, 2017

8.4K
Reverse Genetics Mediated Recovery of Infectious Murine Norovirus
13:48

Reverse Genetics Mediated Recovery of Infectious Murine Norovirus

Published on: June 24, 2012

16.8K

Related Experiment Videos

Last Updated: Oct 8, 2025

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR
15:16

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR

Published on: July 22, 2012

17.4K
Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity
12:57

Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity

Published on: November 16, 2017

8.4K
Reverse Genetics Mediated Recovery of Infectious Murine Norovirus
13:48

Reverse Genetics Mediated Recovery of Infectious Murine Norovirus

Published on: June 24, 2012

16.8K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Noroviruses are leading causes of acute gastroenteritis globally, posing significant public health challenges.
  • The genetic and antigenic diversity of noroviruses complicates the development of broadly effective vaccines.
  • Current limitations include the lack of robust cell culture systems, animal models, and reliable protection markers for vaccine evaluation.

Purpose of the Study:

  • To review recent advancements in norovirus vaccine development, particularly focusing on clinical studies.
  • To summarize the key barriers hindering the progress of norovirus vaccine development.
  • To discuss future perspectives and potential strategies for successful norovirus vaccine design.

Main Methods:

  • Review of recent clinical studies on norovirus vaccine candidates.
  • Analysis of challenges in norovirus vaccine development, including viral diversity and research tools.
  • Discussion of the potential of virus-like particle (VLP) based vaccines.

Main Results:

  • Recombinant virus-like particles (VLPs) mimicking norovirus antigens demonstrate safety and immunogenicity in clinical studies.
  • VLPs show protective efficacy, indicating a high likelihood of developing a useful norovirus vaccine.
  • Despite progress, significant barriers related to viral diversity and research models persist.

Conclusions:

  • Virus-like particle (VLP) based vaccines represent a promising strategy for developing broadly protective norovirus vaccines.
  • Overcoming challenges related to viral diversity and establishing better research models are crucial for future vaccine development.
  • Continued research and clinical evaluation are essential to achieve a successful and widely applicable norovirus vaccine.